Post Profile






Memorial Sloan Kettering Researchers Engineer "Micro-Pharmacies" in CAR T Cells to Treat B Cell Lymphomas

There has been much recent excitement about immunotherapy and the use of genetically engineered chimeric antigen receptor (CAR) T cells. Historically, CAR T cell immunotherapy has aimed to boost the immune system by giving immune cells the information they need to better recognize tumor cells as foreign and attack them. New work led by Hans-Guido Wendel, MD, of Memorial Sloan Kettering Cancer Center, and collaborator Karin Tarte of the University of Rennes, France, illustrates an untapped potential of CAR T cells to act as targeted delivery vehicles that can function as "micro-pharmacies" for precise therapeutic delivery.
read more

share

Related Posts


Cancer-Fighting Gene Immunotherapy Shows Promise as Treatment for HIV

Health : Newswise Medical News

Researchers from the UCLA AIDS Institute and Center for AIDS Research found that recently discovered potent antibodies can be used to generate a specific type of cell called chimeric antigen receptors, or CARs, that can be used to k...

More Chimeric Antigen Receptor Based Cancer Targeting

Health / Aging : Fight Aging

Immune cells can be engineered to selectively target cancer cells for destruction via use of chimeric antigen receptors that match up with proteins that are more common on the exterior of a cancer cell. This strategy has been in the...

An Update on Efforts to Use Chimeric Antigen Receptor T-Cells as a Treatment for Cancer

Health / Aging : Fight Aging

Engineering a patient's own T-cells to express chimeric antigen receptors (CARs) has shown considerable promise as a cancer treatment. This alteration steers the immune cells to attack tumor cells, and has for example been used to d...

Dual antigen targeting may improve CAR T cell cancer therapy

Academics / General Science : Science Codex

Chimeric antigen receptor T cells (CAR T cells) are a promising immunotherapy approach to cancer treatment in which a patient's own immune cells attack tumors by targeting an identifying marker, or antigen, that is displayed at high...

New CAR T cell therapy using double target aimed at solid tumors

Academics / General Science : Science Codex

PHILADELPHIA - Chimeric antigen receptors (CARs), engineered from a patient's own immune cells, have been successful for treating blood cancers, but using CARs for solid tumors has been limited by side effects to normal tissues cont...

Comments


Copyright © 2016 Regator, LLC